Q-omics provides the consensus-scored GRIN2C profile across patient tissues and cancer cell-line models. GRIN2C expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GRIN2C is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, GRIN2C RNA expression shows 16,638 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and THCA as cancer lineages where GRIN2C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRIN2C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRIN2C survival associations across molecular data types. GRIN2C RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRIN2C RNA expression–survival associations across cancer types. High GRIN2C expression shows unfavorable associations in ACC, KIRP, COAD and UCEC, but favorable associations in SCLC and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GRIN2C RNA expression.
This table summarizes GRIN2C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for GRIN2C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRIN2C shows lower tumor expression in THCA and READ and higher tumor expression in LIHC, COAD, BRCA and CHOL. The THCA box plot shows higher GRIN2C RNA expression in normal versus tumor tissue (log2 FC = −4.715, t-test p < 0.001).
This table shows molecular features associated with GRIN2C in patient tissues and cancer cell lines. In patient samples, GRIN2C shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, GRIN2C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SOFT_TISSUE.
